Insights

Innovative Cancer Therapies DEM BioPharma is developing next-generation cancer treatments with its lead ADC program, DEM301, targeting personalized oncology solutions which indicates potential demand for advanced biopharma technologies and partnerships in the oncology space.

Growing Market Presence With an estimated revenue of up to 25 million dollars and a small but focused team, DEM BioPharma is positioning itself as a key player in biotech research, providing opportunities for strategic collaborations, funding, and licensing arrangements.

Recent Leadership Expansion The addition of high-profile scientific advisors like Wendy Young suggests ongoing growth and validation of its research pipeline, opening avenues for partnerships with academic institutions and research organizations.

Technological Capabilities Utilizing advanced tech stacks including PWA and HTTP/3, DEM BioPharma’s emphasis on technology indicates potential for collaboration with firms specializing in pharmaceutical IT, data management, and biotech software solutions.

Funding and Investment Potential Although current funding data is not specified, DEM BioPharma’s revenue range and active R&D focus suggest an opportunity for investment, grants, or joint ventures aimed at accelerating drug development and commercialization efforts.

Similar companies to DEM Biopharma, Inc.

DEM Biopharma, Inc. Tech Stack

DEM Biopharma, Inc. uses 8 technology products and services including oEmbed, Google Fonts API, PWA, and more. Explore DEM Biopharma, Inc.'s tech stack below.

  • oEmbed
    Dev Tools
  • Google Fonts API
    Font Scripts
  • PWA
    Miscellaneous
  • PHP
    Programming Languages
  • HTTP/3
    Web & Portal Technology
  • Nginx
    Web Servers
  • Apache
    Web Servers
  • LiteSpeed
    Web Servers

DEM Biopharma, Inc.'s Email Address Formats

DEM Biopharma, Inc. uses at least 1 format(s):
DEM Biopharma, Inc. Email FormatsExamplePercentage
FLast@dembiopharma.comJDoe@dembiopharma.com
48%
First@dembiopharma.comJohn@dembiopharma.com
2%
LastF@dembiopharma.comDoeJ@dembiopharma.com
2%
FLast@dembiopharma.comJDoe@dembiopharma.com
48%

Frequently Asked Questions

Where is DEM Biopharma, Inc.'s headquarters located?

Minus sign iconPlus sign icon
DEM Biopharma, Inc.'s main headquarters is located at 1 Kendall Sq, Cambridge, Massachusetts 02139, US. The company has employees across 2 continents, including North AmericaAsia.

What is DEM Biopharma, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
DEM Biopharma, Inc.'s official website is dembiopharma.com and has social profiles on LinkedInCrunchbase.

What is DEM Biopharma, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
DEM Biopharma, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does DEM Biopharma, Inc. have currently?

Minus sign iconPlus sign icon
As of October 2025, DEM Biopharma, Inc. has approximately 22 employees across 2 continents, including North AmericaAsia. Key team members include Chief Executive Officer: N. G.Chief Scientific Officer: L. F.Co-Founder, Scientific Advisory Board Co-Chair: K. W.. Explore DEM Biopharma, Inc.'s employee directory with LeadIQ.

What industry does DEM Biopharma, Inc. belong to?

Minus sign iconPlus sign icon
DEM Biopharma, Inc. operates in the Biotechnology Research industry.

What technology does DEM Biopharma, Inc. use?

Minus sign iconPlus sign icon
DEM Biopharma, Inc.'s tech stack includes oEmbedGoogle Fonts APIPWAPHPHTTP/3NginxApacheLiteSpeed.

What is DEM Biopharma, Inc.'s email format?

Minus sign iconPlus sign icon
DEM Biopharma, Inc.'s email format typically follows the pattern of FLast@dembiopharma.com. Find more DEM Biopharma, Inc. email formats with LeadIQ.

When was DEM Biopharma, Inc. founded?

Minus sign iconPlus sign icon
DEM Biopharma, Inc. was founded in 2022.

DEM Biopharma, Inc.

Biotechnology ResearchUnited States11-50 Employees

DEM BioPharma is pioneering the next generation of cancer therapeutics. Our lead program, DEM301, is an antibody-drug conjugate (ADC) targeting a novel extracellular protein that is overexpressed in gastrointestinal and other malignancies.

Section iconCompany Overview

Headquarters
1 Kendall Sq, Cambridge, Massachusetts 02139, US
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2022
Employees
11-50

Section iconFunding & Financials

  • $10M$25M

    DEM Biopharma, Inc.'s revenue is estimated to be in the range of $10M$25M

Section iconFunding & Financials

  • $10M$25M

    DEM Biopharma, Inc.'s revenue is estimated to be in the range of $10M$25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.